SCHEMBL13510674

SCHEMBL13510674

CCn1nc(-c2ccccc2)c(-c2ccsc2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2A6 P11509 2/20 0.50
▸ CYP2B6 P20813 2/20 0.50
▸ CYP2E1 P05181 1/20 0.50
▸ ADORA1 P30542 3/20 0.46
▸ ADORA2A P29274 3/20 0.46
▸ NPY5R Q15761 1/20 0.41
▸ PTGER1 P34995 2/20 0.41
▸ ADORA3 P0DMS8 1/20 0.40
▸ NR1H4 Q96RI1 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ MAPT P10636 2/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ USP2 O75604 1/20 0.38
▸ TNNI3 P19429 1/20 0.38
▸ CRHBP P24387 1/20 0.38
▸ MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13243234 0.84 KMT2A (0.47) ADORA1ADORA3MAPTALDH1A1KDM4E
SCHEMBL8212283 0.83 CYP2A6 (0.53) CYP2A6CYP2B6CYP2E1ADORA1ADORA2A
SCHEMBL13509082 0.82 CYP2A6 (0.48) CYP2A6CYP2B6CYP2E1ADORA1ADORA2A
SCHEMBL14294732 0.81 KDR (0.44) CYP2A6ALDH1A1MEN1KMT2AGAA
SCHEMBL17280145 0.77 CASP1 (0.42) ADORA1ADORA3MAPTALDH1A1KDM4E
SCHEMBL13510675 0.75 ADORA1 (0.45) ADORA1ADORA2APTGER1ADORA3CYP3A4
SCHEMBL14294733 0.74 NR1H2 (0.54) ADORA1ADORA2ANR1H4CYP3A4CYP2C9
SCHEMBL13510669 0.73 PDPK1 (0.54) CYP2A6ADORA1ADORA2AADORA3MAPT
SCHEMBL13996078 0.72 CYP2A6 (0.57) CYP2A6CYP2B6CYP2E1ADORA1ADORA2A
SCHEMBL13510721 0.72 NR1H3 (0.44) ADORA1ADORA3MAPTALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7662779-B2 Triazolyl macrocyclic hepatitis C serine protease inhibitors ENANTA PHARMACEUTICALS, INC. (US) 2010-02-16 — — US disclosed
US-20090047248-A1 TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS ENANTA PHARMACEUTICALS, INC. 2009-02-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090047248-A1 TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS SPINT2, PRSS1, CTSC CYP2A6 308/4885CYP2B6 307/4885CYP2E1 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback